Provided by Tiger Trade Technology Pte. Ltd.

Gene Editing

337.87
+4.191.25%
Number of Gainers:2
Number of Losers:2
Number of Flat:- -
PE:- -
High:349.63
Open:332.15
Low:327.72
Close:333.69
Volume:25.08M
Turnover:369.60M
Market Cap:7.60B
Float Cap:7.17B

Loading ...

Intellia Shares Gain Attention After FDA Priority Review And Trial Progress

Simply Wall St.
·
11 hours ago

Intellia Therapeutics, Inc.: Files for Mixed Shelf Offering; Size not Disclosed - SEC Filing

THOMSON REUTERS
·
Yesterday

Intellia Therapeutics files automatic mixed securities shelf

TIPRANKS
·
Yesterday

CRISPR Therapeutics (CRSP) Could Be 46% Undervalued After Fresh CTX310 Data

Simply Wall St.
·
Nov 18

Need To Know: The Consensus Just Cut Its Beam Therapeutics Inc. (NASDAQ:BEAM) Estimates For 2027

Simply Wall St.
·
Nov 18

Intellia Therapeutics (NTLA) Faces A Fresh Valuation Test After Phase 3 Enrollment Wraps

Simply Wall St.
·
Nov 18

Intellia Therapeutics (NTLA) Receives a Buy from Canaccord Genuity

TIPRANKS
·
Nov 16

Seawolf Therapeutics: Series a Financing by Versant Ventures, Mpm Bioimpact, Novartis Venture Fund, Eli Lilly, Crispr Therapeutics & Others

THOMSON REUTERS
·
Nov 16

Have Editas Medicine Insiders Been Selling Stock?

Simply Wall St.
·
Nov 15

Intellia Therapeutics Stock In Focus As HAE Gene Editing Wins Priority Review

Simply Wall St.
·
Nov 14

Analysts Offer Insights on Healthcare Companies: Capricor Therapeutics (CAPR) and Intellia Therapeutics (NTLA)

TIPRANKS
·
Nov 14

Positive Trial Data Might Change The Case For CRISPR Therapeutics Stock

Simply Wall St.
·
Nov 13

Alpha Cognition Appoints Caren Deardorf to Board

Reuters
·
Nov 13

CRISPR Therapeutics Advances Gene-Editing Trial for High Blood Pressure

TIPRANKS
·
Nov 13

Intellia's Lonvo-Z Cuts HAE Attack Rate 81% Versus Prior Prophylaxis in Phase 3 Trial

Reuters
·
Nov 12

Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026

GlobeNewswire
·
Nov 12

Century Therapeutics Q3 Net Loss Narrows, Beats Analyst Expectations

Reuters
·
Nov 12

TScan Therapeutics Q3 Revenue Drops After Amgen Collaboration Ends

Reuters
·
Nov 12

Switzerland's Pharvaris Q3 Loss Widens as Costs Rise

Reuters
·
Nov 12

Does Pivotal Sickle Cell Trial Success Change The Bull Case For Beam Therapeutics (BEAM)?

Simply Wall St.
·
Nov 12